Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,861
archived clinical trials in
Bladder Cancer

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Charleston Cancer Center
1063
mi
from
Charleston, SC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Charleston Cancer Center
1063
mi
from
Charleston, SC
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Medical University of South Carolina
1063
mi
from
Charleston, SC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Medical University of South Carolina
1063
mi
from
Charleston, SC
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
The Jones Clinic, PC
481
mi
from
Germantown, TN
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
The Jones Clinic, PC
481
mi
from
Germantown, TN
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
The West Clinic, PC
477
mi
from
Memphis, TN
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
The West Clinic, PC
477
mi
from
Memphis, TN
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Lone Star Oncology Consulants, Pa
517
mi
from
Austin, TX
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Lone Star Oncology Consulants, Pa
517
mi
from
Austin, TX
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Cancer Specialists Of South Texas, Pa
694
mi
from
Corpus Christi, TX
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Cancer Specialists Of South Texas, Pa
694
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
The Center for Cancer and Blood Disorders
348
mi
from
Fort Worth, TX
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
The Center for Cancer and Blood Disorders
348
mi
from
Fort Worth, TX
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
University of Texas Medical Branch at Galveston
609
mi
from
Galveston, TX
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
University of Texas Medical Branch at Galveston
609
mi
from
Galveston, TX
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
South Texas Oncology and Hematology
571
mi
from
San Antonio, TX
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
South Texas Oncology and Hematology
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Northern Utah Associates
788
mi
from
Ogden, UT
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Northern Utah Associates
788
mi
from
Ogden, UT
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Cancer Outreach Associates, PC
874
mi
from
Abingdon, VA
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Cancer Outreach Associates, PC
874
mi
from
Abingdon, VA
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Virginia Oncology Associates
1186
mi
from
Norfolk, VA
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Virginia Oncology Associates
1186
mi
from
Norfolk, VA
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Univ. Of Washington Medical Ctr., Prostate-Oncology Ctr
1410
mi
from
Seattle, WA
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Univ. Of Washington Medical Ctr., Prostate-Oncology Ctr
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
West Virginia University
970
mi
from
Morgantown, WV
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
West Virginia University
970
mi
from
Morgantown, WV
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Local Institution
636
mi
from
Milwaukee, WI
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Local Institution
636
mi
from
Milwaukee, WI
Click here to add this to my saved trials
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated:  11/6/2015
Local Institution
8344
mi
from
Tweed Heads,
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy
Status: Enrolling
Updated: 11/6/2015
Local Institution
8344
mi
from
Tweed Heads,
Click here to add this to my saved trials
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer
Status: Enrolling
Updated:  11/19/2015
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer
Status: Enrolling
Updated: 11/19/2015
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Click here to add this to my saved trials
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
A Study Evaluating the Safety and Tolerability of Percutaneous Vaccination Prior to Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Mycobacteria for Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  12/1/2015
University of Texas Health Science Center
571
mi
from
San Antonio, TX
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
A Study Evaluating the Safety and Tolerability of Percutaneous Vaccination Prior to Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Mycobacteria for Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 12/1/2015
University of Texas Health Science Center
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
Markers of Response to Intravesical Bladder Cancer Therapy
Markers of Response to Intravesical Bladder Cancer Therapy
Status: Enrolling
Updated:  12/2/2015
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Markers of Response to Intravesical Bladder Cancer Therapy
Markers of Response to Intravesical Bladder Cancer Therapy
Status: Enrolling
Updated: 12/2/2015
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Status: Enrolling
Updated:  12/8/2015
Weill-Cornell Medical College
1289
mi
from
New York, NY
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Status: Enrolling
Updated: 12/8/2015
Weill-Cornell Medical College
1289
mi
from
New York, NY
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
369
mi
from
Little Rock, AR
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
369
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
USC/Norris Comprehensive Cancer Center and Hospital
1168
mi
from
Los Angeles, CA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
USC/Norris Comprehensive Cancer Center and Hospital
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cancer Centers of Central Florida, PA
1109
mi
from
Leesburg, FL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cancer Centers of Central Florida, PA
1109
mi
from
Leesburg, FL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kapiolani Medical Center at Pali Momi
3719
mi
from
Aiea, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kapiolani Medical Center at Pali Momi
3719
mi
from
Aiea, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cancer Research Center of Hawaii
3717
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cancer Research Center of Hawaii
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
OnCare Hawaii, Incorporated - Lusitana
3717
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
OnCare Hawaii, Incorporated - Lusitana
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Queen's Cancer Institute at Queen's Medical Center
3717
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Queen's Cancer Institute at Queen's Medical Center
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Straub Clinic and Hospital, Incorporated
3717
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Straub Clinic and Hospital, Incorporated
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Hawaii Medical Center - East
3717
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Hawaii Medical Center - East
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
OnCare Hawaii, Incorporated - Kuakini
3715
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
OnCare Hawaii, Incorporated - Kuakini
3715
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kapiolani Medical Center for Women and Children
1307
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kapiolani Medical Center for Women and Children
1307
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Tripler Army Medical Center
4143
mi
from
Honolulu, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Tripler Army Medical Center
4143
mi
from
Honolulu, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Maui Memorial Medical Center
3659
mi
from
Wailuku, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Maui Memorial Medical Center
3659
mi
from
Wailuku, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Pacific Cancer Institute - Maui
3659
mi
from
Wailuku, HI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Pacific Cancer Institute - Maui
3659
mi
from
Wailuku, HI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Decatur Memorial Hospital Cancer Care Institute
499
mi
from
Decatur, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Decatur Memorial Hospital Cancer Care Institute
499
mi
from
Decatur, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
600
mi
from
Maywood, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
600
mi
from
Maywood, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Regional Cancer Center at Memorial Medical Center
463
mi
from
Springfield, IL
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Regional Cancer Center at Memorial Medical Center
463
mi
from
Springfield, IL
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
646
mi
from
Beech Grove, IN
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
646
mi
from
Beech Grove, IN
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Reid Hospital & Health Care Services
710
mi
from
Richmond, IN
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Reid Hospital & Health Care Services
710
mi
from
Richmond, IN
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
190
mi
from
Kansas City, KA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
190
mi
from
Kansas City, KA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Olathe Cancer Center
178
mi
from
Olathe, KA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Olathe Cancer Center
178
mi
from
Olathe, KA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Highland Clinic
433
mi
from
Shreveport, LA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Highland Clinic
433
mi
from
Shreveport, LA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
423
mi
from
Shreveport, LA
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
423
mi
from
Shreveport, LA
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
University of Michigan Comprehensive Cancer Center
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Battle Creek Health System Cancer Care Center
738
mi
from
Battle Creek, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Battle Creek Health System Cancer Care Center
738
mi
from
Battle Creek, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Mecosta County Medical Center
764
mi
from
Big Rapids, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Mecosta County Medical Center
764
mi
from
Big Rapids, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated:  12/8/2015
Josephine Ford Cancer Center at Henry Ford Hospital
841
mi
from
Detroit, MI
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Status: Enrolling
Updated: 12/8/2015
Josephine Ford Cancer Center at Henry Ford Hospital
841
mi
from
Detroit, MI
Click here to add this to my saved trials